Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tideglusib vs placebo in children and adolescents with congenital myotonic dystrophy (DM1)
2016-004623-23Phase 2Unknown
- Sponsor
- AMO Pharma Limited
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myotonic dystrophy type 1 (DM1) comparing Tideglusib with Placebo (2 arms). Primary endpoint: Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS). Status: unknown.
02
Drugs
tideglusib
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on 2016-004623-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004623-23.